25 pts w/ refractory Juvenile dermatomyositis (JDM) were treated w/ JAK inhib (tofacitinib, ruxolitinib) - all showed improved rashes, including 66.7% with complete resolution; 40% had decreased muscle strength; 28% discontinued glucocorticoids https://t.co/wln0FrI0Iz